Dexlansoprazole Pellets
Dual delayed-release pellets targeting extended acid suppression, ideal for once-daily GERD control with staged gastric release.
Product overview
Dexlansoprazole is a proton pump inhibitor and the R-enantiomer of lansoprazole. Its DDR formulation is designed around two delayed-release phases. Rraynex applies controlled pelletization and coating processes to produce uniform multiparticulates suitable for capsule filling, sachets, and other dosage-form development programs.
Key characteristics
- Dual delayed-release pellet technology.
- Controlled coating and dissolution characteristics.
- Uniform pellet size and surface properties.
- Suitable for capsule and multiparticulate formulations.
- Technical support for development, scale-up, stability, and regulatory documentation.
Product specifications
- Product
- Dexlansoprazole Pellets
- Form
- Pellets
- Therapeutic category
- Anti-Ulcerant (PPIs)
- Available strengths
- 15%, 17%, 20%, 22.5%
- Grade
- IP / BP / USP / EP
- Pack size
- 25/50 kg
- Site certifications
- WHO-GMP, ISO 9001, ISO 14001
Detailed specifications, COA and technical documentation are shared on request.
Supply and enquiries
Rraynex supplies Dexlansoprazole Pellets to pharmaceutical manufacturers, formulation developers and CDMOs in 25/50 kg packs with batch traceability. Send your quantity, grade and documentation needs through the enquiry form and the commercial team will reply with specifications and a quotation. Rraynex is a B2B supplier and does not sell to consumers.
Send product enquiry Browse all pellets Manufacturing capabilities
Other Dexlansoprazole products from Rraynex
- Dexlansoprazole DDR — Pellets
- Dexlansoprazole MUPS — Pellets